CoChat

Modulation of Amphetamine-Induced Dopamine Release by Group II Metabotropic Glutamate Receptor Agonist LY354740 in Non-Human Primates Studied with Positron Emission Tomography

van Berckel, Bart N M, Kegeles, Lawrence S, Waterhouse, Rikki, Guo, Ningning, Hwang, Dah-Ren, Huang, Yiyun, Narendran, Rajesh, Van Heertum, Ronald, Laruelle, Marc · 2006 · Neuropsychopharmacology

The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.

Abstract

Pharmacological evidence suggests that schizophrenia is associated with increased stimulation of dopamine (DA) D2 receptors. Recently, several groups have demonstrated that amphetamine-induced DA release is increased in schizophrenia, providing direct evidence for dysregulation of DA systems in this condition. In healthy volunteers, pretreatment with the noncompetitive N-methyl-D-aspartate (NMDA) antagonist ketamine increases amphetamine-induced DA release to levels similar to those observed in patients with schizophrenia. Therefore, the dysregulation of DA function observed in schizophrenia might be secondary to NMDA hypofunction. In this study, the regulation of this response by glutamate (GLU) transmission was further characterized by using a metabotropic glutamate (mGlu) receptor group II agonist to inhibit GLU transmission. The amphetamine- (0.5 mg/kg intravenously (i.v.)) induced decrease in [11C]raclopride equilibrium-specific binding (V3'') was measured under control conditions and following pretreatment with the mGlu2/3 receptor agonist LY354740 (20 mg/kg i.v.) in four baboons. Amphetamine reduced [11C]raclopride V3'' by 28+/-7% under control conditions. Following LY354740 pretreatment, amphetamine-induced reduction in [11C]raclopride V3'' was significantly enhanced (35+/-7%, p=0.002). The enhancement of the amphetamine-induced reduction in [11C]raclopride V3'' by LY354740 was not a simple additive effect, as LY354740 alone did not reduce [11C]raclopride V3''. In conclusion, the results of this study further document the involvement of GLU transmission in regulating the effect of amphetamine-induced DA release, and provide additional support to the hypothesis that the dysregulation of DA function revealed by the amphetamine challenge in schizophrenia might stem from a deficit in GLU transmission.

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.npp.1300902

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Research works printed but not linked: 1

  1. Kim SE, Shin I, Oh SJ, Kim SH, Choe YS, Choi Y et al (1998). Nicotine-induced dopamine release evaluated with in vivo3H raclopride binding studies: comparison with in vivo dialysis data. J Nucl Med 39: 54P.

Cited by

See all 43

Metadata

Authors
van Berckel, B. N. M., Kegeles, L. S., Waterhouse, R., Guo, N., Hwang, D.-R., Huang, Y., Narendran, R., Van Heertum, R., & Laruelle, M.
Affiliations
Columbia University (US)
Venue
Neuropsychopharmacology
Published
2005-09-21
Volume
31
Issue
5
Pages
967-977
ISSN
  • 0893-133X (ISSN-L)
  • 1740-634X
OpenAlex
W2049064370
Cited by
43
References
70
Citations by year
2020: 1 · 2019: 1 · 2018: 1 · 2017: 1 · 2015: 1 · 2014: 2 · 2013: 3 · 2012: 2
FWCI
2.81
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Neuropsychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Funders
  • National Alliance for Research on Schizophrenia and Depression
  • National Institutes of Health (5k08mh001594-05, 5p30mh059342-02)
  • National Institute of Mental Health (K02 MH01603, K02MH001603, MH59342-01, 1 K08 MH01594)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
amphetamine-induced dopamine release, group II metabotropic glutamate receptors, LY354740, glutamatergic neurotransmission, schizophrenia, ketamine, [11C]raclopride, D2 receptor binding, baboons, dopamine dysregulation
MeSH terms
Amphetamine, Animals, Bridged Bicyclo Compounds, Brain, Dopamine, Female, Male, Radioligand Assay, Schizophrenia, Dopamine Agents, Receptors, N-Methyl-D-Aspartate, Receptors, Dopamine D2, Receptors, Metabotropic Glutamate, Dopamine Antagonists, Excitatory Amino Acid Agonists, Raclopride, Papio anubis, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.